Inactive Instrument

Dignitana AB Stock Swiss Exchange

Equities

DIGN

SE0002108001

Medical Equipment, Supplies & Distribution

End-of-day quote Swiss Exchange
- SEK - Intraday chart for Dignitana AB

Financials

Sales 2024 * 120M 11.42M 15.63M Sales 2025 * 174M 16.59M 22.7M Capitalization 121M 11.52M 15.76M
Net income 2024 * 3M 286K 391K Net income 2025 * 21M 2M 2.74M EV / Sales 2024 * 1.04 x
Net Debt 2024 * 3.2M 305K 417K Net cash position 2025 * - 0 0 EV / Sales 2025 * 0.69 x
P/E ratio 2024 *
-
P/E ratio 2025 *
5 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 68.27%
More Fundamentals * Assessed data
Managers TitleAgeSince
Director of Finance/CFO 53 22-06-30
Chairman 64 19-12-31
Chief Tech/Sci/R&D Officer 46 22-02-28
Members of the board TitleAgeSince
Chairman 64 19-12-31
Director/Board Member 61 19-12-31
Director/Board Member 51 20-12-31
More insiders
Dignitana AB is a Sweden-based medical technology company. It develops, manufactures and markets a medical device primarily used for scalp cooling in order to eliminate or reduce chemotherapy induced hair loss. The Company focuses on the product DigniCap, which counteracts hair loss during chemotherapy. The product is a cold cap, which when put on the patient’s head, lowers the temperature of the scalp. The low temperature reduces perfusion, delivery of blood and metabolism. The reduced blood flow results in a smaller amount of chemotherapy available for uptake in the cells, while the decreased temperature results in less absorption and reduced effects of chemotherapy. These factors together reduce the risk of hair loss. The DigniCap scalp cooling system is patented in Europe, Japan and the United States. It has a subsidiary BrainCool AB, which focuses on producing different models of brain cooling for stroke and cardiac arrest patients.
Calendar
More about the company